Confidence in masked T cell engagers builds with Janux update

Investors added over a billion dollars to Janux’s market cap on Tuesday, after updated Phase Ia data from its T cell engager therapy provided early validation for the hypothesis that conditionally active biologics can have impressive efficacy.

Janux Therapeutics Inc. (NASDAQ:JANX) reported that JANX007, which targets CD3 and PSMA, led to PSA declines of at least 50% in all 16 heavily pre-treated prostate cancer patients, when used pre-Pluvicto in the target dose range of 2-9 mg. In the subgroup, 63% achieved a 90% reduction in PSA, while 31% saw PSA levels drop by 99%...